Bellerophon enrolls first patient in Phase 3 INOpulse study

Bellerophon Therapeutics

Bellerophon Therapeutics (NASDAQ:BLPH) enrolled the first patient in its Phase 3 REBUILD study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of fibrotic interstitial lung disease (fILD).

The study will enroll 300 fILD patients who are at risk of pulmonary hypertension on long-term oxygen therapy. Patients will be randomized to receive either INOpulse or placebo for a 16-week blinded treatment period, after which patients may enter into an open-label extension. The study’s primary endpoint is the change in moderate-to-vigorous physical activity.

“The REBUILD study builds on the positive results from our Phase 2 trial that demonstrated the safety and efficacy of INOpulse in improving moderate-to-vigorous physical activity, multiple quality of life measures and key hemodynamic parameters,” Fabian Tenenbaum, Bellerophon’s CEO, said in a statement.

“Importantly, our current balance sheet provides us with the resources to continue advancing this program through the availability of these Phase 3 data and we look forward to sharing topline results from this important study in 2022,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.